PRESS RELEASES

The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) has been carried out in collaboration with the contract...
Redeye Growth Day takes place on June 2 in Stockholm and will be a combination of a digital platform and live presentations. Lipum is "In Focus"...
CEO Einar Pontén comments: “More progress was made in the preparations ahead of clinical trials. In parallel, and in accordance with our strategy...
Pelago Bioscience AB is a fast-growing Swedish company, based in Solna, with bioanalytical expertise and services for drug discovery and development. Pelago...
Lipum is member of the consortium together with both industry and academic partners. The project is led by the Cardiovascular Research Centre (CVRC) at...
The aim of Annual European Congress of Rheumatology EULAR 2022 is to provide a forum of the highest standard for scientific (both clinical and basic)...
2022-03-25 06:00 Lipum AB – Year-end report 2021 Regulatory
CEO Einar Pontén comments: “The last quarter of the year was largely characterized by the fact that we completed activities that constitute...
Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of becoming a new treatment...
Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The...
2022-02-02 13:00 Lipum recruits scientist
Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising...

INVESTOR RELATIONS